This study was an external analysis of the viability of supporting oxytocin in the Uniject™ injection system as a niche product in both the public and private sectors globally. A major component of this analysis was to conduct separate market analyses of 30 countries identified by the US Agency for International Development as priority countries for maternal health interventions.